AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Deutsche Bank AG in a research note issued to investors on Tuesday. They presently have a GBX 5,500 ($67.93) price objective on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target points to a potential upside of 12.24% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. Berenberg Bank increased their price target on shares of AstraZeneca plc from GBX 5,450 ($67.31) to GBX 5,670 ($70.03) and gave the stock a “buy” rating in a research note on Monday. Barclays PLC reaffirmed an “overweight” rating and set a GBX 6,000 ($74.10) price target on shares of AstraZeneca plc in a research note on Monday. Goldman Sachs Group Inc set a GBX 3,900 ($48.17) price target on shares of AstraZeneca plc and gave the stock a “sell” rating in a research note on Thursday, March 16th. Beaufort Securities reaffirmed a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, March 16th. Finally, Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of GBX 5,018.36 ($61.98).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4900.00 on Tuesday. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The stock’s market capitalization is GBX 62.00 billion. The stock’s 50 day moving average is GBX 4,617.49 and its 200 day moving average is GBX 4,602.58.

The business also recently disclosed a dividend, which was paid on Monday, March 20th. Shareholders of record on Thursday, February 16th were issued a dividend of GBX 150.20 ($1.86) per share. This is a positive change from AstraZeneca plc’s previous dividend of $68.70. This represents a yield of 3.52%. The ex-dividend date of this dividend was Thursday, February 16th.

Your IP Address:

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.